Cladribine

證據等級: L5

預測適應症: 7 個

Cladribine: From Hairy Cell Leukemia to Parameningeal Embryonal Rhabdomyosarcoma

One-Sentence Summary

Cladribine is a purine nucleoside (deoxyadenosine) analog historically used to treat hairy cell leukemia, acting through selective cytotoxicity to lymphocytes and monocytes via DNA double-strand breaks. The TxGNN model predicts possible activity against Parameningeal Embryonal Rhabdomyosarcoma (score 99.77%), but this is currently a pure graph-based association — 0 clinical trials and 0 publications support this specific prediction, and no mechanistic link between cladribine's known biology and rhabdomyosarcoma has been identified.

Quick Overview

Item	Content
Original Indication	Hairy cell leukemia (general drug knowledge; no license/indication record present in evidence pack)
Predicted New Indication	Parameningeal Embryonal Rhabdomyosarcoma
TxGNN Prediction Score	99.77% (rank 2900)
Evidence Level	L5 — model prediction only, no clinical or literature support
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Structured MOA data was not available in the evidence pack (original_moa: [Data Gap]). However, the model's own rationale field describes cladribine as a lymphocyte/monocyte-selective cytotoxic deoxyadenosine analog, working through DCK-mediated phosphorylation and induction of DNA double-strand breaks — this is consistent with its established clinical role in hairy cell leukemia, a lymphoid/monocytic hematologic malignancy.

Parameningeal embryonal rhabdomyosarcoma, in contrast, is a skeletal-myoblast-lineage solid tumor with a fundamentally different cell of origin and proliferative biology. The evidence pack's own repurposing rationale explicitly states there is no known direct mechanistic connection between cladribine's lymphocyte-targeted cytotoxicity and rhabdomyosarcoma pathogenesis — the high TxGNN score reflects a graph-relationship prediction, not a validated pharmacological hypothesis.

This pattern is consistent across all 7 ranked predictions in this evidence pack (5 rhabdomyosarcoma subtypes, rhabdomyosarcoma as a general category, and liver sarcoma) — all are scored L5/Hold, and none have supporting mechanistic rationale. The single literature hit found anywhere in this evidence pack (PMID 15241520, under rank 7 "liver sarcoma") concerns cladribine's use in smoldering systemic mastocytosis — a hematologic mast-cell disorder, not a sarcoma — and does not constitute relevant supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Cytotoxicity

Cladribine is a conventional cytotoxic antineoplastic (purine nucleoside/deoxyadenosine analog, antimetabolite class), currently used in hematologic malignancy treatment.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — purine nucleoside (deoxyadenosine) analog / antimetabolite
Myelosuppression Risk	Mechanistically expected to be significant, as the drug's activity depends on selective lymphocyte/monocyte depletion via DNA double-strand breaks; no quantified hematologic toxicity data available in this evidence pack — please refer to the package insert
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	CBC with differential (particularly lymphocyte count), liver and renal function
Handling Protection	Antineoplastic — cytotoxic drug handling precautions apply

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA/Fimea package insert warnings and contraindications are recorded as a Blocking data gap (DG001) in this evidence pack — this must be resolved before any safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: This candidate has L5 evidence only — a TxGNN association score with zero supporting clinical trials or literature, and no identified mechanistic link between cladribine's known lymphocyte/monocyte-selective cytotoxicity and rhabdomyosarcoma biology. All 7 predicted indications in this evidence pack share the same Hold status for the same reason. The drug is also not currently marketed in Finland, and safety/label data required for even a preliminary safety assessment (S1) is missing.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — currently a Blocking gap (DG001)
Verified original indication and MOA data from DrugBank (DG002)
Preclinical or mechanistic studies specifically linking cladribine to rhabdomyosarcoma or sarcoma biology
Drug-drug interaction data
Re-screening of lower-ranked candidates as new trial/literature evidence accumulates
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.